Received October 15, 2018
Accepted February 28, 2019

Objetive: To evaluate the effects of three different estrogen luteal phase support protocols on pregnancy rate, as well as luteal phase hormone profile in vitro fertilization–embryo transfer (IVF-ET) cycles. And secondary objective to evaluate which ovarian reserve marker relates to pregnancy rate. Methods: Retrospective, observational study. One hundred four patients who were undergoing intracytoplasmic sperm injection with antagonist protocol of controlled ovarian hyperstimulation. Intervention: Women were divided in three groups according to administration route of estrogen in luteal phase support: oral (Primogyna), transdermal patches (Estradott), or transdermal gel (Oestrogel Pump). These administration routines of estrogen are equivalent to 4 mg of estradiol daily. All women received 600mg of vaginal progesterone (P) per day (Utrogestan) in luteal phase support. Blood samples were drawn on the day of hCG administration, as well as beta hCG day for E2 and P measurements. Results: Patient features in the three groups were comparable. No significant differences were found concerning implantation rate, clinical PR, miscarriage rate, multiple-pregnancy rate, or E2 and P levels on beta hCG day. Concerning ovarian reserve markers, a significant relationship between positive test of clinical pregnancy and AMH was observed (r = 0.66, p<.0001), as well as with E2 level on beta hCG day (r = 0.77; p <.0001). Conclusions: In IVF-ET cycles with GnRH antagonist, no significant difference was observed on pregnancy rates when adding either oral, transdermal patches, or transdermal gel E2 to P during the luteal phase and clinical pregnancy rate correlates with AMH and E2 level on beta hCG day.